London shares ended lower on Friday, with the FTSE 100 down 0.32% at closing, as investors weighed the latest central bank policy decisions, UK consumer spending momentum and a pullback in oil prices.
UK monthly retail sales volumes increased 0.5% in August after declining 0.5% in July, according to data from the Office for National Statistics. The result exceeded expectations for a 0.2% fall. Year over year, retail sales rose 2.4%, following a 1.2% increase in July and ahead of expectations for 1.9% growth.
"August's sales numbers cap a relatively strong 12 months of volume growth for the retail sector. With inflation yet to see the full effect of the Middle East conflict, consumers' incomes rising in real terms, and the hot weather as well, consumer confidence has risen to the highest level we've seen in five years. That in turn has led to this strong run of performance," PwC commented.
Speaking of the Middle East, Reuters reported that China had privately asked Iran to help restrain Yemen's Houthis following a request from Saudi Arabia. The appeal came after Houthi forces made advances along Yemen's Red Sea coast and around the Bab el-Mandeb Strait, increasing risks to Saudi oil exports and shipping through a key global trade route.
On the corporate front, telecommunications and mobile money services provider Airtel Africa (AAF.L) dropped the most on the blue-chip index, falling 9.88% at closing, after Bloomberg News reported that the planned London initial public offering of its Airtel Money unit could be smaller than previously indicated. The business is reportedly considering an IPO of at least $800 million, lower than the previous target range of $1.5 billion to $2 billion.
Meanwhile, AstraZeneca (AZN.L) edged up 0.02% after the European Medicines Agency's Committee for Medicinal Products for Human Use recommended extending the indication for its and Daiichi Sankyo's Enhertu to the adjuvant treatment of patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer. The recommendation covers use of the drug as a monotherapy.
The panel also recommended the approval of AstraZeneca's Alexion unit's Klygefa for generalized myasthenia gravis, a rare chronic autoimmune disease.